Hormone Refractory Breast Cancer - Insights | Hope |Treatment Modality

According to a new report published by Allied Market Research, Hormone Refractory Breast Cancer, Breast cancer is one of the most common type of malignant cancers, which is prevalent in women above 40 years. As per World Health Organization (WHO) estimates, breast cancer accounted for around 521,000 deaths globally in 2012. Generally, hormone therapies are used for treating breast cancer, which subsequently leads to resistance after continuous use of hormone therapy. This resistance towards hormone therapy is termed as hormone refractory breast cancer.

Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-toc-and-sample/1468

The key factors driving growth of this market include, increasing global incidences of breast cancers, uprising prevalence rates of hormone refractory breast cancers, ageing population, demands of advanced therapeutics and increasing R&D investment on breast cancer drugs. The factors restraining the market growth are the social stigma related to breast cancer examinations, and insufficient advanced chemotherapeutic treatments.

Key Takeaways:

Resistance to Hormone Therapy: Hormone refractory breast cancer, also known as hormone-resistant or hormone-insensitive breast cancer, is characterized by the tumor's reduced or complete lack of response to hormone-based therapies such as tamoxifen or aromatase inhibitors.

Challenging Subset: Hormone refractory breast cancer represents a challenging subset of breast cancer cases, particularly in postmenopausal women. This resistance often develops after an initial period of response to hormonal treatments.

Genetic Variability: Genetic mutations and changes in hormone receptor status can contribute to the development of hormone resistance. Tumors may develop new hormone receptors, making them less responsive to traditional hormone-based treatments.

Individualized Treatment: Precision medicine plays a pivotal role in managing hormone refractory breast cancer. Tailoring treatment plans to a patient's unique genetic and molecular profile allows for more effective therapies and better outcomes.

Tumor Marker Analysis: Tumor marker-based therapies involve the identification of specific markers in the tumor to guide treatment decisions. This approach minimizes side effects and optimizes treatment effectiveness.

Gene Expression Profiling: Gene expression profiling helps identify the genetic characteristics of the tumor, allowing for personalized treatment approaches. This is crucial in targeting the underlying genetic factors driving resistance.

Targeted Therapies: Novel therapies, such as PARP inhibitors and other targeted agents, are being investigated for their effectiveness in hormone refractory breast cancer. These therapies aim to disrupt the cancer's growth pathways.

Ongoing Research: The field of hormone refractory breast cancer is dynamic, with ongoing research efforts seeking to better understand its mechanisms and develop more effective treatments. Clinical trials are a critical part of advancing care for affected patients.

Key Benefits :

The analysis, made in this report, helps in understanding the strategies adopted by various companies for gaining market share in hormone refractory breast cancer market

The report provides the quantitative analysis of the current market and estimations that assists in identifying the prevailing market opportunities to capitalize on

This report provides a comprehensive analysis of factors that drive and restrict the growth of the hormone refractory breast cancer market

Detailed study of the strategies of key leaders, partnerships, and acquisitions in the global hormone refractory breast cancer market would be informative for professionals in the corporate sector

Pin-point analysis of geographic segments helps to identify opportunities for growth within the hormone refractory breast cancer market

Identification of key investment pockets for hormone refractory breast cancer market provide strategic assistance to decision makers

An analysis for the market attractiveness has been included for therapeutics, devices, and geographic regions along with a detailed analysis of factors responsible for the rapid growth of the market segments

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/1468

Competitive Landscape:

AmpliMed Corporation

Bioenvision Limited

Teva Pharmaceutical Industries Ltd

Bluefish Pharmaceuticals AB

Eli Lilly and Company

AstraZeneca plc

F. Hoffmann-La Roche Ltd.

Neopharm Ltd.

Boehringer Ingelheim GmbH.

NeoCorp GmbH

Market Segments:
By Treatment Modality:

Hormone receptor-based therapy

Tumor markers therapy

Gene expression therapy

Gene mutation therapy

By Region:

North America (U.S., Canada, Mexico)

Europe (France, Germany, Italy, Spain, UK, Rest of Europe)

Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)

LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)

Obtain Report Details:

https://www.alliedmarketresearch.com/hormone-breast-cancer-market

Contact
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter

About Us:

Allied Market Research is market research, consulting, and advisory firm of Allied Analytics LLP. Founded in 2013, the firm has been instrumental in offering high-quality syndicated and customized market research reports, consulting services, and useful insights to leading market players, startups, investors, and stakeholders. Driven by the aim to eliminate sub-standard data and become a successful partner for organizations, Allied Market Research has been innovating continuously, expanding the product & service portfolio, and implementing the client-first approach since its inception. With the clientele spanning more than 7,000 organizations that also include most of the Fortune 500 companies, AMR has a proven track record of helping and serving the global clientele and playing a major role in their success.

This release was published on openPR.